Study identifier:SD-039-0698
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Effects of high dose inhaled budesonide+ formoterol versus placebo and oral prednisolone on biomarkers of airway inflammation in the treatment of exacerbations in non-hospitalised patients with mild to moderate COPD.
Chronic obstructive pulmonary disease (COPD)
Phase 2
No
-
All
120
Interventional
40 Years +
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|